Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan.
Since 1985, a nationwide program of mass screening for neuroblastoma has been available for 6-month-old infants throughout Japan. From 1985 to 1993, the authors studied 285 patients with neuroblastoma among their regional population of 15 million. There was an increase in the total number of patients per year in comparison to the previous 6-year period (1979 to 1984). However, no significant difference was noted in the number of patients older than 1 year or in the incidence of advanced-stage (stages III and IV) unscreened cases. The majority of neuroblastomas in the screened group showed favorable biological factors, even in the advanced stages. However, there was a small group with histologically and/or biologically unfavorable factors; five of 115 had amplified N-myc oncogene, four of 74 showed unfavorable Shimada histological findings, and three of 33 had an unfavorable DNA ploidy pattern. One case from this group with unfavorable factors died of the tumor. 3) Thirty-eight cases were negative at the time of mass screening, but later presented with neuroblastoma. Most of them were diagnosed between 1 and 3 years of age, and 30 of the 38 cases (78.9%) were advanced stage with unfavorable prognostic factors. Thus, the authors conclude that mass screening at 6 months can detect a selected population of infants with neuroblastoma; some of the tumors may represent subclinical masses destined for spontaneous regression. However, some tumors with unfavorable factors have been detected by mass screening before progression and/or dissemination. Infants in this group are considered to benefit most from early diagnosis and treatment.
Suita
S
S
Department of Pediatric Surgery, Kyushu University, Fukuoka, Japan.
Zaizen
Y
Y
Sera
Y
Y
Takamatsu
H
H
Mizote
H
H
Ohgami
H
H
Kurosaki
N
N
Ueda
K
K
Tasaka
H
H
Miyazaki
S
S
Sugimoto
T
T
Kawakami
K
K
Tsuneyoshi
M
M
Yano
H
H
Akiyama
H
H
Ikeda
K
K
D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003404:Creatinine / Q000652:urine; D005260:Female; D005500:Follow-Up Studies; D006719:Homovanillic Acid / Q000652:urine; D006801:Humans; D007223:Infant; D007564:Japan / Q000453:epidemiology; D008297:Male; D008403:Mass Screening; D008479:Mediastinal Neoplasms / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D011003:Ploidies; D016271:Proto-Oncogene Proteins c-myc / Q000032:analysis; D012186:Retroperitoneal Neoplasms / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D012983:Soft Tissue Neoplasms / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D015996:Survival Rate; D014642:Vanilmandelic Acid / Q000652:urine
D014408:Biomarkers, Tumor; D016271:Proto-Oncogene Proteins c-myc; D014642:Vanilmandelic Acid; D003404:Creatinine; D006719:Homovanillic Acid